Anwen Liu

Nanchang University - Department of Medical Oncology

Nanchang

China

SCHOLARLY PAPERS

2

DOWNLOADS

87

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Toripalimab Plus Chemotherapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (Choice-01): Final Os and Biomarker Exploration of a Randomized, Double-Blind, Phase 3 Trial

Number of pages: 37 Posted: 02 Aug 2024
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Central South University - Thoracic Medicine Department II, Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Jilin Cancer Hospital, China Medical University - Medical Oncology Department of Thoracic Cancer, Guangdong Pharmaceutical University - Department of Medical Oncology, Xuzhou Central Hospital, Jiangnan University - Affiliated Hospital, Chinese Academy of Sciences (CAS) - Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Harbin Medical University, Wenzhou Medical University - Taizhou Hospital of Zhejiang Province, Linyi Cancer Hospital - Department of Medical Oncology, Zhejiang University - Second Affiliated Hospital, The First Affiliated Hospital of Guangxi Medical University, Shanghai Jiao Tong University (SJTU) - Department of Respiratory and Critical Care Medicine, Tangshan People’s Hospital, Shandong University - Shandong Cancer Hospital, Qingdao Central Hospital, ZhongDa Hospital of Southeast University, Huazhong University of Science and Technology - Department of Medical Oncology, Nanchang University - First Affiliated Hospital, Zhengzhou University - Henan Cancer Hospital, Government of the People's Republic of China - Second People's Hospital of Yibin, Peking University - Department of Thoracic Medical Oncology, Medical School of Nanjing University, Xiamen University - First Affiliated Hospital, Nanjing Medical University - Jiangsu Cancer Hospital, Zhengzhou University - Department of Oncology, Xinjiang Medical University - Affiliated Tumor Hospital, China Medical University - Department of Medical Oncology, Qingdao University - Affiliated Hospital, Nanchang University - Department of Medical Oncology, Shandong University - Qilu Hospital, Shanghai Pulmonary Hospital, Tianjin Medical University - Department of Medical Oncology, Nanjing University - Department of Respiratory Medicine, Anhui Provincial Cancer Hospital, Anhui Medical University - Department of Respiratory and Critical Care Medicine, Guangzhou Medical University - Second Affiliated Hospital, Army Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Peking Union Medical College Hospital, Tongji University - Department of Respiratory and Critical Care Medicine, Nantong Tumor Hospital - Department of Medical Oncology, First People's Hospital of Changzhou, Chongqing Medical University - Second Affiliated Hospital, Jilin University (JLU) - Cancer Center, Shanghai Jiao Tong University (SJTU) - Ruijin Hospital of Shanghai, Yangzhou University - Subei People's Hospital of Jiangsu Province, Anhui Provincial Cancer Hospital, Shanxi Provincial People's Hospital, Shanxi Provincial People's Hospital, Chinese Academy of Medical Sciences - Cancer Hospital, Nanjing Medical University - Nanjing First Hospital, Nanjing Medical University - Department of Oncology, ChangZhou Cancer Hospital, Nantong University - Department of Respiratory Medicine, First Hospital of Jiaxing, Fujian Provincial Cancer Hospital, Ground Force Medical University - Xinqiao Hospital, Xi’an Jiaotong University, Health Science Center, First Affiliated Hospital, TopAlliance Biosciences, TopAlliance Biosciences, Burning Rock Biotech - Department of Medicine, Burning Rock Biotech, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Shanghai Junshi Biosciences Co., LTD, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology and Chinese Academy of Medical Sciences & Peking Union Medical College - State Key Laboratory of Molecular Oncology
Downloads 45 (824,020)

Abstract:

Loading...

Non-small cell lung cancer, overall survival, immunotherapy, biomarker

2.

Efficacy and Safety of KL-A167 in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Single-Arm, Phase 2 Study

Number of pages: 33 Posted: 22 Mar 2022
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Guangdong Pharmaceutical University - Department of Medical Oncology, Sichuan University - Collaborative Innovation Center for Biotherapy, Guangxi Medical University - Department of Respiratory Oncology, Jiangxi Cancer Hospital - Department of Head and neck radiotherapy, Fujian Medical University - Department of Radiation Oncology, Fujian Medical University - Department of Radiation Oncology, Yue Bei People's Hospital - Department of Oncology Radiotherapy, Zhejiang University - Department of Medical Oncology, Nantong Tumor Hospital - Department of Oncology Radiotherapy, Chongqing Medical University - First Affiliated Hospital, The People's Hospital of Guangxi Zhuang Autonomous Region - Department of Head and neck surgery, Guangzhou University of Chinese Medicine - Department of Oncology, Fujian Medical University - Department of Radiation Oncology, Zhengzhou University - Henan Cancer Hospital, Liuzhou Worker’s Hospital - Department of Medical Oncology, Central South University - Hunan Cancer Hospital, Anhui Provincial Cancer Hospital, Nanjing Medical University - Jiangsu Cancer Hospital, Guangdong Medical University - Department of Oncology, Fudan University - Internal Medicine Oncology, Government of the People's Republic of China - Department of Oncology, Nanchang University - Department of Medical Oncology, Huazhong University of Science and Technology - Department of Oncology, Hebei Medical University - Fourth Hospital, Harbin Medical University - Department of Medical Breast oncology, Nanjing Medical University - Department of Oncology, Shanghai Jiao Tong University (SJTU) - Shanghai General Hospital, Fujian Medical University - Department of Radiation Oncology, Guizhou Medical University (Guiyang Medical University) - Department of Head and Neck oncology, Haikou People’s Hospital - Department of Medical Oncology, Linyi Cancer Hospital - Department of Medical Oncology, Tianjin Medical University - Department of Oncology Radiotherapy, Jilin University (JLU) - Cancer Center, Huazhong University of Science and Technology - Cancer Center, Wenzhou Medical University - Department of Medical Oncology, Yunnan Cancer Hospital, Central South University - Department of Oncology, Central South University - Department of Oncology, Shandong University - Department of Head and Neck neoplasm, Dalian University - Department of Oncology, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Downloads 42 (846,921)

Abstract:

Loading...

KL-A167, nasopharyngeal carcinoma, efficacy, safety, PD-L1, biomarker